Boswellic Acids in Chronic Inflammatory and Cancer Therapies

Boswellic acids are a family of pentacyclic triterpenes derived from the resin of Boswellia species, traditionally used in Ayurvedic and other ethnomedicinal systems. They exert potent anti-inflammatory effects through inhibition of key enzymes and signalling cascades such as 5-lipoxygenase and nuclear factor-κB, leading to reduced synthesis of leukotrienes and pro-inflammatory cytokines. In chronic inflammatory conditions—rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and asthma—boswellic acids have demonstrated symptom relief, preservation of tissue integrity and improved barrier function in preclinical and early clinical studies. In oncology, specific derivatives such as acetyl-11-keto-β-boswellic acid (AKBA) have been shown to induce tumour-cell apoptosis, arrest cell cycle progression, inhibit angiogenesis and suppress metastatic potential across a range of solid tumours. Despite challenges in bioavailability and pharmacokinetics, formulation strategies and combination approaches continue to enhance systemic exposure and therapeutic index. Collectively, the dual anti-inflammatory and anti-neoplastic properties of boswellic acids underscore their global significance as multifunctional agents with potential roles as adjuvants or lead compounds in the management of chronic inflammatory diseases and cancer.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Research from all publishers

Recent investigations into the anti-inflammatory activity of boswellic-rich essential oils have demonstrated strong antioxidant capacity comparable to synthetic controls, coupled with suppression of cell membrane lysis and protein denaturation in vitro. These studies highlight the capacity of frankincense essential oil to stabilise inflammatory mediators and support its use as a complementary approach in inflammatory disorders. A comprehensive pharmacological review has summarised boswellic acids’ multi-target mechanisms in chronic diseases, detailing interactions with transcription factors, kinases and growth factors, while also addressing bioavailability challenges and advanced delivery systems designed to overcome absorption barriers. In oncology, acetyl-11-keto-β-boswellic acid has been shown to arrest glioblastoma cells at the G2/M checkpoint, downregulating cyclin B1 and Aurora kinases, inducing mitochondrial-mediated apoptosis and achieving significant tumour growth inhibition in xenograft models, thereby positioning AKBA as a promising candidate for further clinical development in aggressive brain tumours.

Boswellic Acids in Chronic Inflammatory and Cancer Therapies publication trend

The graph below shows the total number of articles in boswellic acids in chronic inflammatory and cancer therapies across all publications each year (not limited to Nature Index journals).

Technical terms

Pentacyclic triterpene: A class of five-ringed natural compounds, including boswellic acids, with diverse bioactive properties.

5-lipoxygenase: An enzyme that catalyses leukotriene synthesis and promotes inflammatory responses.

Nuclear factor-κB (NF-κB): A transcription factor central to the regulation of immune and inflammatory gene expression.

Acetyl-11-keto-β-boswellic acid (AKBA): A highly active boswellic acid derivative noted for its anti-tumour and anti-inflammatory potency.

G2/M arrest: A checkpoint in the cell cycle where cells are prevented from entering mitosis, often targeted to inhibit tumour proliferation.

Apoptosis: Programmed cell death characterised by caspase activation, DNA fragmentation and membrane blebbing.

References

1. Boswellia Essential Oil: Natural Antioxidant as an Effective Antimicrobial and Anti-Inflammatory Agent. Antioxidants (2023).
2. An Update on Pharmacological Potential of Boswellic Acids against Chronic Diseases. International Journal of Molecular Sciences (2019).
3. Boswellia serrata Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage. PLOS ONE (2015).
4. 3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase. Journal of Experimental & Clinical Cancer Research (2018).